Mukka Proteins Limited has informed the Exchange about completion of the acquisition of Ento Proteins Private Limited.
MUKKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mukka Proteins Limited has completed the acquisition of the remaining stake in Ento Proteins Private Limited (EPPL), making it a 100% Wholly Owned Subsidiary effective 23rd February 2026. The company acquired 1,000 equity shares of face value Rs. 100 each for a total cash consideration of Rs. 32.30 lakhs. EPPL manufactures insect meal and insect oil, operating in the alternative proteins space, with FY25 turnover of Rs. 7.46 crores and profit after tax of Rs. 49.47 lakhs. The turnover has grown steadily from Rs. 4.72 crores in FY23 to Rs. 7.46 crores in FY25. The acquisition is part of Mukka Proteins' strategic plan to expand its alternate proteins business.
Positive strategic move for shareholders — gives Mukka Proteins full control over a growing, profitable subsidiary in the alternative protein segment. The deal size is small, so limited immediate financial impact, but it consolidates Mukka's presence in a high-growth future-facing vertical.